Blog

Purification of Oligonucleotides with Polymeric Reverse Phase HPLC Resins

Oligonucleotides of DNA and RNA are important for therapeutic, diagnostic, and research uses. Reverse Phase High Pressure Liquid Chromatography (RP-HPLC) is frequently chosen for preparative chromatography when high purity oligonucleotides are desired.

Read more

DuPont™ AmberChrom™ Fine Mesh Ion Exchange Resins for Peptide and Oligonucleotide Column Separations

AmberChrom™ fine mesh ion exchange resins have many design features that impact performance, giving peptide drug developers many degrees of freedom to design purification processes that balance impurity removal with ease of operation. 

Read more

DuPont Water Solutions and Xenon arc Launch directibility™

DuPont Water Solutions and Xenon arc Launch directibilityb"


BELLEVUE, Wash.--(BUSINESS WIRE)--DuPont Water Solutions, in partnership with Xenon arcbs DWS Advantage, is excited to announce the launch of directibilityb", a new online commerce solution at www.DWSAdvantage.com. This industry-leading platform provides quick and simple access to DuPont Water Solutionsb multi-technology portfolio. Trusted by millions, DuPont Water Solutions ultrafiltration, reverse osmosis, and ion exchange resin technologies have led the water treatment industry for quality, reliability, and safety for over 70 years.

bOur goal for the DuPont Water Solutions business is to continue to make it easier for our customers and channel partners to access our product portfolio, and look forward to creating new ways to connect and service all of our customer segments."

Built by Xenon arc, directibilityb" is designed to provide another way for customers to have direct access to products while still receiving personalized support from the DWS Advantage team. By investing in the customer experience and building lasting relationships, directibilityb" is a new channel to gain greater access to DuPont products.

bWe are excited to give our customers additional options to learn about and purchase our industry-leading products through the launch of directibilityb",b said Peter Ingarra, Americas Commercial Director. bOur goal for the DuPont Water Solutions business is to continue to make it easier for our customers and channel partners to access our product portfolio, and look forward to creating new ways to connect and service all of our customer segments.b

The upgraded site provides a wide array of options including easier access to product discovery, purchasing, product research, technical support through online chat, order history and documents, all in one place. Signup is free and includes access to DWS Advantagebs full product portfolio of over 250 products that services industrial, commercial, municipal, pharmaceutical and residential markets: Amber Series, FilmTecb", FortiLifeb", ingeB. Dizzerb", Ligasepb", TapTecb", and IntegraFluxb".

bThe launch of directibilityb" for DuPont Water Solutions is an exciting development for both Xenon arc and DWSAdvantage,b commented Mica Zuniga, Senior Vice President of Strategic Growth Initiatives at Xenon arc. bThe expanded offering speaks to the quality and integrity of DuPontbs leading product portfolio and will enable us to further address the complex technical and service needs of select customers and distributors in North America.b

About DuPont Water Solutions

Dupont Water Solutions is part of DuPont Water & Production organization, a global leader in delivering innovation for lifebs essential needs in water, shelter and safety; enabling its customers to win through unique capabilities, global scale and iconic brands including DuPontb" CorianB., KevlarB., NomexB., TyvekB., GreatStuffb", Styrofoamb" and FilmTecb". More on DuPont Water Solutions can be found at https://www.dupont.com/water.

About DWS Advantage

DWS Advantage was established in 2020 as a direct channel-to-market supplier of DuPont Water Solutionbs multi-technology portfolio to select customers in North America and Western Europe. DWS Advantagebs dedicated team of experts focus on providing customers a seamless experience through personalized support, flexible purchasing options, and extensive access to the DuPont Water Solution brands. Through an innovative market support strategy and digital tech-enabled platform, DWS Advantage provides customers an easy way to transact and acquire the right products to support their business operations. Additional information can be found at www.DWSAdvantage.com

About Xenon arc

Established in 2010, Xenon arc is a data-driven marketing and sales company, focused on enhancing the way materials producers engage with their Small-to-Mid-Sized-Business customers and segments. Xenon arcbs xa-DIRECT model, featuring Conntactb" and directibilityb" technology platforms, specializes in building private label, direct-to-market teams. With offices in the US, Europe, Mexico and Brazil, Xenon arc partners with producers looking to evolve, digitize, and enhance their go-to-market strategy. Xenon arcbs client list includes some of the most distinguished brands in the materials industry and is constantly expanding. For more information, visit www.xenonarc.com.

Contacts

Mica Zuniga
Senior Vice President, Strategic Growth
m. 425.518.0382
e. mica.zuniga@xenonarc.com

DuPont Invests in Bioprocessing Supply Chain to Enhance Purchasing of its Products for Drug Development

WILMINGTON, Del., February 8, 2022, b DuPont (NYSE:DD) has launched a new online sales portal tailored to the needs of bioprocessing industry purchasers. The portal handles online sales transactions, with target lead times of < 1 week.

DuPontbs bioprocessing solutions enable sophisticated purifications and separations for therapeutics and diagnostics, with brands such as DuPontb" AmberChromb" and DuPontb" AmberLiteb" being well established in the biopharma industry. Its products are used to purify process streams during drug and diagnostic kit manufacturing. Although these products are not part of the finished formulation, purification resins are critical to final product quality and are therefore selected early in drug development.

The e-store is created in collaboration with DWS Advantage, a Xenon arc entity, and provides customers with direct access to DuPont products while still giving them personalized support from the DWS Advantage team. The new online store answers the need in the bioprocessing market for speed and agility, allowing direct access to DuPont's resins in a format suitable for benchtop and early process development phases of drug development. 

The e-store can be accessed at: Life Sciences (dwsadvantage.com)

The interactive website provides researchers with quick and easy transactions that meet their project timelines. The online store is structured in a way that guides product selection based on researchersb project needs. Customers will discover interactive features that allow them to connect to the DWS Advantage team for immediate sales support and access DuPontbs technical service and development team for pre-sale and post-sale queries relating to their purchase.

bThe addition of this new store to the DWS Advantage online site is an exciting development for both Xenon arc and DuPont,b commented Alyssa Cunnington, COO at Xenon arc. bAdding the Life Sciences product offering to the DWS Advantage online store speaks to the quality and integrity of DuPontbs leading product portfolio and will enable us to better address the complex technical and service needs of bioprocessing customers.b  

Since the 1950s, DuPont has been developing solutions to address complicated separation and purification. Drug manufacturers can have especially difficult purification challenges because product streams often contain structurally similar impurities. As a global market leader in adsorbents and ion exchange resins, DuPont offers a broad range of products specifically designed to be used in bioprocessing and drug synthesis, from advanced gene therapies to conventional small molecule APIs and virus test kits. 

bWe are eager for our customers to experience the DuPont brand in a new way. Our new e-commerce portal will give customers a convenient way to buy our products while continuing to benefit from the top-notch service they would get when purchasing traditionally,b said Dorie Yontz, DuPont Water Solutions bioprocessing global marketing manager.  bThe biopharma industrybs rapid response to COVID over the past two years highlights the urgency in new drug development.  Drug researchers are solving real-world problems, treating and curing life-changing conditions.  Speed to clinic is critical, and our Life Science store is addressing that need for rapid delivery of convenient product forms to support drug research.b   

 

About DuPont Water & Protection

DuPont Water and Protection is a global leader in creating water, shelter and safety solutions for a more sustainable world; enabling its customers to win through unique capabilities, global scale and iconic brands including KevlarB., NomexB., TyvekB., CorianB. Design, GreatStuffb", Styrofoamb", and FilmTecb".

 

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

 

About DWS Advantage

DWS Advantage, DWS, a Xenon arc entity, was established in 2019 as a direct channel-to-market supplier of DuPont Water Solutionbs multi-technology portfolio to select customers in North America and Western Europe. DWS Advantagebs dedicated team of experts focus on providing customers a seamless experience through personalized support, flexible purchasing options, and extensive access to the DuPont Water Solution brands. Through an innovative market support strategy and digital tech-enabled platform, DWS Advantage provides customers an easy way to transact and acquire the right products to support their business operations. Additional information can be found at www.DWSAdvantage.com.

Considering Purification and Separation in the Downstream Train

3D Motion

Emerging drug classes are giving rise to challenges in downstream processing, pushing the need for strategizing efficiencies.

The global downstream processing (DSP) market is predicted to experience compound annual growth rate of 16.09% between 2021 and 2027 (1). This market growth is reportedly being driven by the expanding biopharmaceutical industry and spending in medical research, the rising adoption of single-use technology in bioprocessing, and the swell of contract manufacturing organizations in the market for DSP (1).

To learn more about purification and separation of biopharmaceuticals, the fundamental challenges facing developers, ways in which companies can overcome bottlenecks associated with DSP, sustainability considerations, and other trends impacting this sector, BioPharm International spoke with Dorie Yontz, global market manager, Bioprocessing, DuPont Water Solutions, and Hans J. Johansson, global applications director, Purolite.

Techniques and technology overview

BioPharm: Could you provide an overview of the main techniques and technologies employed for separation and purification?

Yontz (DuPont Water Solutions): The type of DSP depends on the type of molecule. Most fermentation and cell culture processes start with some type of particulate separation system (centrifugation or depth filtration) to separate cells from the product in the liquid continuous phase. This is followed by a primary purification step to separate and concentrate the target drug from the bulk of the impurities in the dilute feed. In monoclonal antibodies (mAbs), this is an affinity chromatography step in which the product is captured. In peptides and other fermentation products, it may be an ion exchange or adsorptive chromatography step where product is captured based on its hydrophobicity. Additional polishing chromatography steps may be needed further downstream, which are designed to tackle the impurities via a different separation mechanism to the initial purification.

The choice of chromatography design is dictated by the nature of the impurities and the target product. Where there is a difference in ionic character in the impurities and the product, an ion-exchange chromatography (IEC) approach is preferred. Non-ionic species should be separated by hydrophobic interaction resins, or reverse-phase (RP) resins, depending on the polarity of the molecules and the carrier. In the case of synthetic oligonucleotides, which are a drug category that sits at the interface of conventional pharma and biopharma, either IEC or reverse-phase chromatography (RPC) can be used. In fact, RPC is the workhorse system that can achieve high resolution across a wide range of molecules.

Johansson (Purolite): Even if there are many technologies available today, chromatography based on different types of beads is instrumental for purification in a majority of downstream processes. For mAbs, a standard DSP platform based on Protein A affinity chromatography, followed by one or two additional polishing steps is generally adopted in the market. For other molecules there is less opportunity for general solutions, and, in many cases, no affinity-based solutions are available. In those cases, companies have to rely on putting together orthogonal resins based on size, charge, or hydrophobicity.

Fundamental challenges

BioPharm: What are the fundamental challenges of separation and purification?

Johansson (Purolite): There is an old saying that bthe process is the productb. That is still true in many cases and results in a high threshold for introduction of new technologies. It is thus rare to see changes in established commercial processes. However, with the recent supply challenges where customers report delivery times well above a year for many chromatography resins, this might start to change. We have already seen initiatives in areas such as virus filtration and Protein A affinity chromatography to develop strategies for exchange of resins in registered processes.

Yontz (DuPont Water Solutions): The basic purpose of the DSP train is to provide a high-purity product stream at as high a yield as possible, in as short a time as possible, cost-effectively. In mature processes, particularly platform processes, purity has already been achieved and much of the focus is on throughput and cost-effectiveness. For new drugs, however, particularly those in the emerging drug classes, designing an effective purification scheme can be a challenge, and that is where drug developers work closely with experts, such as DuPont.

Particulate removal with mechanical filters such as depth filters or ultrafiltration is relatively straightforward because this primarily relies on size exclusion, but the separation of soluble species of similar nature is a much bigger challenge. Chromatography is an excellent technique for this because the purification mechanism relies on subtle differences in chemical and physical interactions between the soluble species and the resin. Luckily, there are many chromatography approaches and many degrees of freedom in chromatography variables, so drug developers have a variety of options for designing effective purification techniques.

Overcoming bottlenecks

BioPharm: How can companies overcome the bottleneck issues commonly associated with separation and purification?

Yontz (DuPont Water Solutions): Start-up procedures can be time-consuming, and ensuring processes can continue for as long as possible without having to change out or clean components, such as resins, helps improve speed in DSP.

For example, polymeric RP resin is much more stable than RP silica and can be more aggressively cleaned, extending the time between replacements while providing stable performance and a long lifetime.

Johansson (Purolite): There is an increasing interest in different types of continuous solutions based on multi-column systems. The primary goal is to increase productivity per liter of resin, allowing significant savings in resin and buffer volumes. This is especially relevant in clinical manufacturing where resins commonly are used for only a fraction of their functional lifetime. However, there will always be a balance between complexity, risk, and potential benefits. Thus, solutions that, from an engineering or scientific point of view, are most effective are not necessarily what end up being implemented.

Complex biomolecules

BioPharm: Is the increasing complexity of biomolecules impacting purification and separation?

Johansson (Purolite): While most plain mAbs fit well into existing DSP platforms, this is not always the case for next-generation antibodies that include conjugated, bispecific, and other novel molecule designs. For example, some new antibody-based biomolecules are more prone to aggregation under the acidic conditions used for elution from traditional Protein A resins. For that purpose, Purolite has recently launched a new resin that allows elution at 1b2 pH units above what is now needed to achieve complete recovery.

There has also been an increasing number of larger macromolecules reaching the market. The messenger RNA (mRNA)-based COVID-19 vaccines are an obvious example, but also virus, virus-like particles, and plasmids. The size of these molecules is a challenge for traditional resin design that depends on the diffusion in and out of the particles to achieve high capacities. There are ways to improve the performance of resin beads for these types of molecules, but we might also see an increasing use of other formats, such as nanofibers, monoliths, and membranes.

Yontz (DuPont Water Solutions): The complex drug pipeline will lead to a highly diversified product mix in the future. As therapies become more targeted, we expect to see a wide variety of drug structures. Researchers and manufacturers will need a portfolio of purification strategies, particularly in the chromatography area, to address the differing separation mechanisms, and this is where expert suppliers will be relied upon. The chemical and physical characteristic of oligonucleotides and peptides, for instance, favor separations via RPC, whereas other emerging drug categories may rely on hydrophobic interaction chromatography or affinity chromatography.

Often, we are trying to separate the target active compound from structurally similar impurities. This separation is a delicate balance of chemical and physical interactions with chromatography resin. Particle size, resin morphology, accessible surface area, resin chemistry, and mobile phase all influence resolution and separation kinetics. Platform processes will be more challenging in the future due to the increasing complexity of the drug pipeline, and there will be more focus on resin selection and designing the eluent system to meet the unique purification needs of each drug. Greater collaboration between researchers and resin suppliers will be needed.

Sustainable DSP

BioPharm: How might separation and purification be made more sustainable?

Yontz (DuPont Water Solutions): There is no bone size fits allb as solutions have different benefits and trade-offs. Rather, itbs a matter of looking at the drug process as a whole and deciding which option is the better choice overall. Sustainability and environmental consciousness can come in many forms. For instance, the biopharma industry uses a tremendous amount of water, and, while the single-use trend can reduce water consumption from cleaning, that doesnbt change the fact that fermentation and cell culture processes are inherently water-intensive operations that produce a dilute product stream.

Anything in DSP that ensures high product yield also helps the sustainability picture by maximizing the total output of active drug substance each reactor provides. From that perspective, the most basic thing we look at when choosing the type of purification scheme is the yield. The type of chromatography (IEC, RPC, or adsorption chromatography) and the resin choice can be viewed as contributing to the overall sustainability of the system since it directly impacts product yield. In resin chromatography, there are several resin design aspects that relate to sustainability that we can improve upon.

Process intensification. The size of the column and the number of cycles needed to purify a batch play a key role in the amount of chemicals and solvent (organic solvents or water) that are used in the purification. The ideal resin is one that has good yield and purity at fast flow rates, which allows a smaller column to be used for a given process. Particle size, mechanical stability, and resin morphology all impact the separation kinetics of a resin system and, therefore, impact column sizing and chemical and solvent use.

Eluent profile. RPC relies on organic solvents for the eluent. On the surface, the solvent-based systems may seem counter to the sustainability and environmental trend, but that is not necessarily the case. RPC is a very effective and efficient chromatography technique. There have been several papers in recent years looking at alternative solvent choices to balance resolution and environmental profile and research into solvents from renewable sources (e.g., isobutanol, ethanol, isopropanol, acetone) continues in the bio-based chemical industry, with the hope of creating more sustainable solvent options in the future.

Resin lifetime. The first principle of bGreen Chemistryb is prevention, that is, avoiding waste, and resin lifetime directly relates to this. When designing resin chromatography systems, we should look for resins that can withstand many cleaning cycles and provide consistent performance batch after batch to extend the time between replacement. Polymeric resins are known to be stable to a wider pH range and can therefore be more aggressively cleaned for a longer lifetime compared to silica options.

Johansson (Purolite): Environmental footprint will certainly be important for all businesses in the nearby future. In DSP, there is the use for purification, where more efficient processes will require less resin, buffers, and energy but also the actual manufacturing of the resin. At Purolite we have a continuous way of manufacturing our agarose resins. That process reduces the carbon footprint, water, and solvent consumption by up to 80% compared to the traditional batch emulsification method that other manufacturers rely solely on.

Potential trends

BioPharm: Are there any particular trends for the future that you believe will be impactful for purification and separation?

Johansson (Purolite): Personalized medicine has been a topic for several decades now. It is a gradual development, but we have already seen some amazing developments. This will increase the pressure to lower cost of purification for very limited patient groups and, thus, small amounts of biopharmaceuticals. In DSP, the trend of increased use of pre-packed column, possibly pre/sterilized, will continue and also move down in scale. One could eventually see a future where specific antibodies are developed for single patients.

Another area is biosimilars. More and more biosimilars are coming to the market and regulatory pathways are developed in most regions over the world. With that comes an increasing pressure to further bring down cost of goods to make global supply possible.

Yontz (DuPont Water Solutions): I think we will see a tremendous growth in the need for oligonucleotide molecules to support the gene therapy market. These molecules do not fit the classic definition of biopharma because oligonucleotides are produced by chemical synthesis rather than fermentation or cell culture, but their mode of action is at the genetic level and involves specific, highly directed interactions in the body similar to that of biologic drugs.

Oligonucleotides have been under investigation for decades, but the segment has gained tremendous momentum in recent years. We should see an increase in RPC, particularly with polymer resins, as these processes scale to large-volume processes to tackle chronic diseases.

Reference

1. Market Research Future, Downstream Processing Market Information by by Technique (Cell Disruption, Solid-Liquid Separation, Clarification/Concentration, Purification Techniques, Formulation), by Product (Chromatography Columns & Resins, Filters, Membrane Adsorbers, other), by Application (Antibiotic Production, Hormone Production, Antibodies Production, Vaccine Production, Other), by End User ( Biopharmaceutical Manufacturers, Contract Manufacturing Organization, Other) Forecast till 2027, Market Report (September 2021).

About the Author

Felicity Thomas is the European editor for BioPharm International.

Article Details

BioPharm International
Vol. 35, No. 3
March 2022
Pages: 21b23

Citation

When referring to this article, please cite it as F. Thomas, bConsidering Purification and Separation in the Downstream Train,b BioPharm International 35 (3) (2022).

Source: https://www.biopharminternational.com/view/considering-purification-and-separation-in-the-downstream-train

The Role and Benefits of Polymeric Resins in Bioprocessing

Dorie Yontz of DuPont discusses its bioprocessing offering, the role of polymeric resins, and critical elements as they relate to manufacturing.

 
Recently, DuPont launched a new online sales portal tailored to the needs of bioprocessing industry purchasers. The companybs bioprocessing solutions are designed to enable sophisticated purifications and separations for therapeutics and diagnostics, with established brands such as DuPont AMBERCHROM and DuPont AMBERLITE for the biopharma industry. 
 
The companybs products are used to purify process streams during drug and diagnostic kit manufacturing. Although these products are not part of the finished formulation, purification resins are critical to final product quality and are therefore selected early in drug development.
 
The new online store aims to support the bioprocessing market for speed and agility, allowing direct access to DuPont Ls resins in a format suitable for benchtop and early process development phases of drug development.
 
Dorie Yontz, Global Market Manager, Bioprocessing, DuPont Water Solutions discusses the bioprocessing offering, the role of polymeric resins, and critical elements as they relate to manufacturing. bKB  
 
Contract Pharma: What were the factors behind DuPontbs addition to its Life Sciences product offering for bioprocessing?
 
Dorie Yontz: We recognize that drug discovery and benchtop research teams have different needs versus commercial scale manufacturing. Biopharma companies are adopting various strategies to shorten drug development timelines and they need speed and agility when it comes to small-scale product screening. Our online e-store was designed to offer these benefits to our customers and, so far, the feedback has been positive. 
 
DuPontbs family of purification resins offers high resolution and yield for complicated separations. Our digital store delivers easy and fast access to these products in convenient small-scale packaging for benchtop research. 
 
Given that the drug pipeline is very diverse, we believe it is important for people to have a means to navigate the product options based on the way they think about their projects, be it based on the type of drug they are purifying, the function they are trying to achieve, or the resin class that they are seeking. The new online store is intuitive and easy to navigate to cater for these requirements. At the same time, users of the platform have access to DuPontbs technical experts for guidance with product selection and troubleshooting, if needed.
 
CP: Please explain the role and benefits of polymeric resins as they relate to pharmaceutical bioprocessing?
 
DY: Drug developers have many strategies for designing effective purification processes, depending on the target molecule and type of impurities. There are numerous parameters that factor into polymer resin design and we have a portfolio of options within the ion exchange, reverse phase chromatography resin, and adsorption resin families. Resin characteristics such as particle size, pore size, accessible surface area, resin chemistry, and mobile phase influence the capacity, resolution, and separation kinetics of the purification process.  
 
Once the best resin for the drug has been identified, the process needs to be scaled and transferred to manufacturing. Development scientists and process technology transfer teams appreciate that our resins consistently perform across a wide range of conditions and readily scale-up, so that they can have confidence in transitioning the drug process through the development phases to commercial manufacturing.
 
End-users also like that our products are robust. The ability to withstand many cleaning cycles without loss of performance is key in extending the time between replacements.  For example, DuPontb" AmberChromb" chromatography resins are stable to a wide pH range and can therefore be more aggressively cleaned compared to silica alternatives, which offers consistent performance and long lifetimes. 
 
Due to the increasing complexity of the drug pipeline, there will be greater focus in the future on resin selection and adapting the eluent system to meet the unique purification needs of each drug. This customization will rely on greater collaboration between researchers and resin suppliers, such as DuPont, during drug discovery and scale-up. 
 
CP: What are the critical elements as they relate to manufacturing?
 
DY: Drug manufacturers need to ensure consistent supply of safe and effective medicines at prices patients can afford. As a key component of the purification process, polymeric resins separate target drug molecules from impurities, while minimizing loss of precious drug product; therefore, resin resolution and its impact on drug yield and purity are critical in a manufacturing environment. Reliable resin supply with on-time delivery and consistent quality batch after batch are also vital since the complex regulatory environment leaves drug manufacturers with limited flexibility to adjust to supply issues. Time is money, and production up-time is a key metric for manufacturers. This means they need to have confidence that their supplier is trustworthy with knowledgeable support staff who can help them when technical issues arise.  
 
For decades, DuPont has been a premier supplier of polymeric ion exchange and chromatography resins that are used in drug processes around the world. Our comprehensive product line and technical expertise allow for exceptional performance in even the most complex manufacturing processes. As a global company, we have operations and technical support staff around the world to help manufacturers with their resin purification processes, from discovery, to clinical trials, to commercial manufacturing.
 
CP: What solutions are available for all phases of drug development from discovery to large-scale commercial production?
 
DY: DuPontbs purification resins have scalable performance from benchtop to commercial production, so the solutions for different phases of drug development are tailored based on convenience for the user. For drug discovery, where researchers often want the convenience of a pre-packed column, resin is available in HPLC column formats. We also have resin in small quantities for those who prefer to pack their own columns. The small sizes are easy for researchers to handle and provide an affordable way to test a range of products so they can see what works best for them.  
 
For large-scale commercial production, we offer a range of polymeric resins including reverse phase resins, fine mesh anion exchange resins, fine mesh cation exchange resins, and adsorbent resins. These products are manufactured in large commercial facilities and can support large volume processes with consistent quality from batch to batch.
 
We are giving our customers an easy route to quickly test our products and select the right one for scale-up, helping them streamline their development and get to market quicker.


Dorie Yontz is the Global Marketing Manager for Bioprocessing, part of the Life Sciences and Specialty group within DuPont Water Solutions (DWS) business.  Before joining DWS in 2016, she spent 7 years leading a wide range of projects at a start-up company dedicated to the development and commercialization of specialty bio-based chemicals. Prior to that, Dorie had a 10-year career with The Dow Chemical Company, serving in a variety of R&D and market development roles across multiple businesses.  She has an MBA from Northwood University and a PhD in Polymer Science and Engineering from the University of Massachusetts, Amherst.

Source: https://www.contractpharma.com/contents/view_online-exclusives/2022-03-14/the-role-and-benefits-of-polymeric-resins-in-bioprocessing/

Guide to Reverse Phase HPLC Method Development for Oligonucleotides

As more companies explore oligonucleotides as part of their biopharma drug pipeline, the importance of developing an effective HPLC method is increasing.

Read more

Comparison of Reverse Phase Resins for Preparative Oligonucleotide Separations

High purity nucleotide oligomers are important for therapeutic and research uses. Obtaining these high purity oligos requires purification steps to remove inpurities generated during the synthesis.

Read more

Purification of Nucleotide Triphosphates: Critical Building Blocks for mRNA Therapies

High-purity nucleotide triphosphates are essential to ensure efficient deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis. Researchers rely on purified nucleotide triphosphates as the building blocks of messenger RNA (mRNA) technology, which is fundamental to applications such as COVID-19 vaccines.

Read more

Guide to Cartridge Purification of Oligonucleotides with DuPont™ AmberChrom™ Resins

High-purity nucleotide triphosphates are essential to ensure efficient deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis. Researchers rely on purified nucleotide triphosphates as the building blocks of messenger RNA (mRNA) technology, which is fundamental to applications such as COVID-19 vaccines. However, commercially available sources of nucleotide triphosphates can be contaminated with mono-, di-, or even tetra-phosphates. This article discusses the importance of high-purity nucleotide triphosphates and how fine mesh anion-exchange resins can be used to purify them. 

Read more